Ongoing studies investigating novel agents in the frontline setting
| Treatment . | Trial . | Phase . | Patients . |
|---|---|---|---|
| BV-CHEP induction followed by BV consolidation | NCT03113500 | 2 | CD30-positive PTCL (≥1% expression) |
| CHOEP +/- duvelisib or oral azacitidine | NCT04803201 (ALLIANCE A051902) | 2 (randomized) | PTCL with ≤10% CD30 expression |
| Golidocitinib + CHOP | NCT05963347 | 2 | PTCL (including sALCL) |
| CHOP followed by selinexor maintenance | NCT05822050 | 2 | PTCL with CR on interim response assessment |
| CHOP +/- intravenous azacitidine and chidamide | NCT05678933 | 3 (randomized) | PTCL-TFH |
| Duvelisib + chidamide | NCT05976997 | 2 | PTCL-TFH |
| CHOP + parsaclisib | NCT05238064 | 1/2 | PTCL |
| CHOP +/- belinostat, COP + pralatrexate | NCT06072131 | 3 | PTCL |
| Azacitidine + chidamide | NCT04480125 | 2 | PTCL unfit for conventional chemotherapy |
| CHOP +/- selinexor with intravenous azacitidine OR duvelisib with intravenous azacitidine OR chidamide with tislelizumab (based on genotype) | NCT05675813 | 1/2 | PTCL |
| Treatment . | Trial . | Phase . | Patients . |
|---|---|---|---|
| BV-CHEP induction followed by BV consolidation | NCT03113500 | 2 | CD30-positive PTCL (≥1% expression) |
| CHOEP +/- duvelisib or oral azacitidine | NCT04803201 (ALLIANCE A051902) | 2 (randomized) | PTCL with ≤10% CD30 expression |
| Golidocitinib + CHOP | NCT05963347 | 2 | PTCL (including sALCL) |
| CHOP followed by selinexor maintenance | NCT05822050 | 2 | PTCL with CR on interim response assessment |
| CHOP +/- intravenous azacitidine and chidamide | NCT05678933 | 3 (randomized) | PTCL-TFH |
| Duvelisib + chidamide | NCT05976997 | 2 | PTCL-TFH |
| CHOP + parsaclisib | NCT05238064 | 1/2 | PTCL |
| CHOP +/- belinostat, COP + pralatrexate | NCT06072131 | 3 | PTCL |
| Azacitidine + chidamide | NCT04480125 | 2 | PTCL unfit for conventional chemotherapy |
| CHOP +/- selinexor with intravenous azacitidine OR duvelisib with intravenous azacitidine OR chidamide with tislelizumab (based on genotype) | NCT05675813 | 1/2 | PTCL |
sALCL, systemic ALCL.